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Ovarian cancer (OC) is one of the most aggressive 
malignancies of female reproductive system, occupy­
ing the fourth place in the structure of cancer incidence 
among Ukrainian women (14.3 per 100 000 women). 
It has one of the highest levels among genital cancer 
patients in Ukraine and other countries as well [1]. 
High mortality in OC patients is caused by the fact that 
75% of OC cases are diagnosed at ІІІ–ІV stage, resul­
ting in poor prognosis of the disease and low efficacy 
of treatment [2].
OC pathogenesis and ethiology are still poorly un­
derstood. Nevertheless, there are several hypothesis 
of the pathology origin. Consistent with one of them, 
the ovarian cancer occurrence is caused by a high 
number of ovulations that leads to enforced prolife­
ration of the ovarian surface epithelium, that fills the 
wound defect arising from follicule rupture. So, the 
number of ovulation cycles during lifetime is an indica­
tor of the OC risk [2, 3].
 Meanwhile, viral infection (by human papilloma 
virus, for example, strains 16, 18, 48, 56) of the ovarian 
epithelium contributes to OC development, especially 
in case of serous neoplasia [4].
 Moreover, genetic factors play an important part 
in OC occurrence. Accumulation of genetic alterations 
has been reported to underlie progressive transfor­
mation of ovarian benign tumors into malignant ones 
[5]. Numerous oncogenes and suppressor genes 
determine ovarian tumors pathogenesis and progres­
sion (acquisition of more malignant features during 
tumor growth). Sporadic OC often carry mutations 
in ТР53 tumor suppressor gene (in 50% of serous 
adenocarcinomas, for example). Epithelial ovarian 
tumors are characterized by changes in expression 
of a number of cell cycle regulators, such as р16INK4a 
(in 35% of OC cases), СDК4, cyclin D and Rb (retino­
blastoma gene) (in 30% of OC cases), and overexpres­
sion of HER2/neu oncogene (in 10–50% cases) [6].
A body of experimental, epidemiological and 
clinical studies allows to characterize OC as a hormone­
dependent tumor. By other words, an essential factor 
in OC pathogenesis is hormonal imbalance determined 
by an increase of pituitary gonadotrophic function, 
resulting in ovulation overstimulation and chronic 
hyperestrogenia along with a decrease in progester­
one secretion. Hyperestrogenia can be considered 
as an additional risk factor of ovarian malignancy [2].
More evidence on OC hormone­dependence was 
presented when estrogens (ER) and progesterone re­
ceptors (PR) were detected. It was shown that ovaries 
produce sex steroid hormones, and they are a target 
of their action simultaneously; i. e. realization of hor­
monal stimuli requires an adequate quantity of the recep­
tors. Ovarian neoplasias are characterized by changes 
in their receptor status, and, consequently, tumors can 
be either primary receptor­negative or as a result of their 
progression they may lost the receptors.
In a number of studies it was shown that both mis­
sense and nonsense mutations (resulting in complete 
loss of expression) in ER genes are common in OC [7].
Steroid hormone receptors are a significant link 
in hormonal signal transduction. They modulate such 
important events, as cell differentiation, proliferation and 
death through interaction with the respective ligands.
ER and PR levels depend on tumor histologic type, 
patients’ age that determines their responsiveness 
to hormonal therapy with synthetic progestagen and 
antiestrogen [8].
It was noticed that receptor status and prolifera­
tive activity determine tumor malignancy and disease 
course [9–12]. However, no consensus on prognostic 
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significance of steroid hormone receptor expression 
levels in ovarian tumors was reached yet.
Immunohistochemistry enables estimation of bio­
markers expression in tumor tissue and determination 
of morphological structures that express them [9, 13].
In the present paper we report the results of the 
retrospective immunohistochemical investigation 
of ER and PR expression and proliferative activity 
in ovarian neoplasias and evaluation of their possible 
prognostic significance.
MATERIALS AND METHODS
The current study was carried out on surgically resected 
tumor samples (including archival ones) from 81 patients 
with serous OC of І–IV stage (16–79 years old, average age 
was 46.6 ± 2.4 years), 42 from which were at menstrual 
period (16–55 years) and 39 — at menopausal period 
(52–72 years). Morphologically not changed serous epi­
thelium samples of endometrial fibromioma cases (n = 7) 
were used as the relative negative control.
All patients underwent treatment in the Oncogyne­
cological Department of the National Cancer Institute 
of Ministry oh Health of Ukraine (headed by prof. Vorobyo­
va) at the period from 1988 to 2005. The stage of tumor 
process was determined according to FIGO classification 
[14]. The data about disease clinical course, treatment 
and patients’ outcome were obtained retrospectively from 
each case history and ambulatory records. Accor ding 
to these data, 20 patients survived for 5–17 years, and 
for 29 patients survival period was < 5 years.
Immunohistochemistry on ER and PR expres­
sion was performed on deparafinized slides, using 
mouse monoclonal antibodies against ER (clone 1D5), 
PR (clone PgR636) and Кі­67 (clone МІВ­1), and En­
Vision visualization complex  (DakoCytomation, Den­
mark) according to manufacturer protocol [15]. Marker 
expression was determined in 700–800 tumor cells.
The results of immunohistochemical reaction were 
evaluated using semiquantitive method [15], using 
calculation of positively stained cells or labelling in­
dex (LI). ER and PR medians were 29.0% and 37.0%, 
respectively. Consistent with these data, LI values less 
and higher than median value Ме were considered 
low and high, respectively. ER or PR expression was 
considered negative when LI ≤ 10%.
Proliferation index (PI) was estimated as the number 
of Ki­67 expressing cells. Proliferation activity was con­
sidered low if PI < 10.0%, and high if PI ≥ 10.0% [15].
Statistical analysis of obtained results was performed 
using description statistic, the comparison of samples 
(Mann — Whitney’s U­test), using program STATISTICA 
6. Survival analysis was provided using Kaplan — Maier 
method; statistical significance of the differences be­
tween survival curves was defined by Cox­test [16–18].
RESULTS AND DISCUSSION
All studied neoplasias were diagnosed as serous 
adenocarcinomas of different grade: G1 (n = 9), G2 
(n = 34) or G3 (n = 38).
We have found that Ki­67 was not expressed 
in normal ovarian epithelial cells. At the same time, 
the majority of serous tumors were highly prolifera­
ting with PI ranging from 10 to 76.3% (average value 
33.6 ± 2.8%). Analysis of steroid hormone recep­
tors in all relative control samples has shown low 
PR (14.2 ± 3.9%) and negative ER expression.
ER and PR expression in ovarian tumors increased 
essentially, compared to that in the nontransformed 
ovarian tissue, and was 29.0 ± 2.6% і 33.0 ± 3.1%, 
respectively (Fig. 1, 2).
a
b
Fig. 1. High expression of estrogen receptors in ovarian cancer 
cells. a, x 400; b, x 900
a
b
Fig. 2. High expression of progesterone receptors in ovarian 
cancer cells. a, x 400; b, x 900
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Positive expression was recorded almost in the 
same number of OC cases: 68.0% of tumors was 
PR positive, and in 67.0% of tumors ER positive. Mean­
while, tumors with low ER and PR expression com­
prised 25.5 and 15.0% of total OC cases. High expres­
sion of these receptors was found in 42.0 and 53.0% 
of total OC cases, respectively. Receptor’s phenotype 
of neoplasm is one of the basic criteria of OC hormone 
sensitivity; together with efficacy of hormonal therapy 
it predetermines the prognosis of the disease.
The analysis of receptor phenotype of studied 
ova rian tumors has shown that 54.0% of cases were 
ER+PR+ positive, and in 21.0% of tumors both receptors 
were not expressed. ER+PR– and ER–PR+ phenotypes 
were determined in 14.0% and 11.0% of the patients. 
The current study has demonstrated the relation­
ship between the expression of steroid hormone recep­
tors and the state of patients’ menstrual function. The 
number of cells expressing ER in the group of patients 
with a restored menstrual function was higher com­
pared to this parameter in patients of menopausal age, 
and were 30.0 ± 2.8% and 26.0 ± 2.4%, respectively. 
For women at menopausal period PR expression was 
reliably lower (27.0 ± 2.9%, р < 0.05) than for patients 
with restored menstrual function (34.0 ± 3.2%).
The results of comparison of ER and PR expression 
in І–ІІ and ІІІ–IV stage OC are shown in Table 1. It was 
shown that a half of І–ІІ stage OC samples expresses 
receptors versus 43.0% in ІІІ–IV stage OC samples. 
Moreover, in the group of ІІІ–IV stage patients’ num­
ber of receptor­negative tumors was the three folds 
increased.
Table 1. Steroid hormone receptor expression in ovarian adenocarcinomas 
of different stages 
Stage of disease 
according to FIGO
Receptor expression profile, % of total case number 
ER+PR+ ER+PR– ER–PR+ ER–PR–
І–ІІ 50.0 12.5 25.0 12.5
ІІІ–ІV 43.0 13.0 12.0 32.0
The investigation of ER and PR expression in ova­
rian neoplasias of different grade has revealed signifi­
cant heterogeneity of this index, especially in G2 and 
G3 tumors (Table 2).
Table 2. ER and PR expression in ovarian neoplasias of different grade
Tumor histologic grade
Labelling index of the biomarker, %
ER
min–max
PR
min–max
G1 51.6 ± 4.6
29–70
51.8 ± 4.3
37–70
G2 31.8 ± 3.6
0–69
37.8 ± 4.7
0–84
G3 21.0 ± 3.9
0–90
24.2 ± 4.4
0–84
ER and PR expression was the highest in G1 tumors 
and decreases along with disease progression reaching 
its minimal values in G3 ovarian carcinomas (p < 0.005).
It should be noted that among patients with 
G1 ovarian tumors, high ER and PR expression was 
prevalent, while lower differentiation grade corre­
sponds to higher numbers of cases with low or nega­
tive receptors expression. ER and PR expression was 
absent in 26.5% of G2 tumors, whereas there was 
a 2­fold increase in the number of such cases among 
G3 carcinomas (Fig. 3).
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Fig. 3. Distribution of ovarian serous adenocarcinomas of dif­
ferent grade according to the level of steroid hormone receptor 
expression
The study of receptor expression has revealed that all 
G1 tumors were positive (ER+PR+ phenotype), while ova­
rian carcinomas of higher grade showed an increase in the 
number of receptor negative (ER–PR–) cases (Table 3).
Table 3. Steroid hormone receptor expression in ovarian adenocarcinomas 
of different grade
Tumor histologic 
grade
Receptor phenotype, %
ER+PR+ ER+PR– ER–PR+ ER–PR–
G1 100.0 – – –
G2 61.7 14.7 8.8 14.7
G3 36.8 15.8 15.8 31.6
In order to estimate the prognostic significance 
of steroid hormone receptor expression, groups 
of OC patients were standardized according to type 
and regimen of applied polychemotherapy.
Based on analysis of survival curves of OC patients, 
it was possible to determine the ER and PR expression 
levels (29.0% and 37.0%) that were of critical pro­
gnostic significance. We have found that 5­year survival 
of 75.0% and 65.0% was reliably higher in OC patients 
with high levels of ER and PR expression (higher than 
29.0% and 37.0%, respectively), compared to patients 
with lower values of expression (Fig. 4).
Obtained data indicate that the expression of steroid 
hormone receptors could be considered as an inde­
pendent prognostic factor in ovarian neoplasias. This 
hypothesis is supported by the number of female re­
productive system malignancy studies, showing a great 
importance of receptor status in hormone­dependent 
tumors. For example, Ellinidi et al. [19] have reported 
on estrogen­and­progesterone receptor phenotype 
as an important prognostic parameter, reflecting the 
presence of two pathogenetic pathways of breast 
cancer development. Meanwhile, it was shown that 
endometrial neoplasms that expreesed ER and PR were 
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characterised by low grade, insignificant depth of mio­
metrium invasion, low number of metastases in re­
gional lymph nodes and better survival, compared to the 
negative cases. It is noteworthy, that the expression 
of ER and PR is important for the course and outcome 
of endometrial cancer [20]. However, for prognosis 
of OC outcome PR expression is considered to be most 
valuable [8, 9]. The prognostic significance of ER ex­
pression is far from being completely determined, but 
there is some evidence that the loss of estrogen recep­
tor β promotes OC development [21]. 
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Fig. 4. Survival curves for OC patients dependent on ER (a) and 
PR (b) expression
In conclusion, the current study shows that serous 
OC is characterised by high proliferative activity and 
increased expression of steroid hormone receptors 
compared to those in the nonchanged ovarian surface 
epithelium. It was shown that ER and PR expression 
depends on tumor histologic grade and varies between 
the tumors of the same grade. The receptor phenotype 
of serous ovarian tumors correlates with disease stage, 
and level of steroid hormone receptor expression is one 
of the significant factors that determine OC patients’ sur­
vival. Proliferative activity and steroid hormone receptor 
status along with clinical and morphological characteris­
tics of the disease have prognostic significance and may 
be used for evaluation of serous OC course.
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